PMID- 33297453
OWN - NLM
STAT- MEDLINE
DCOM- 20210708
LR  - 20210708
IS  - 2073-4409 (Electronic)
IS  - 2073-4409 (Linking)
VI  - 9
IP  - 12
DP  - 2020 Dec 7
TI  - Effect of Beta 3 Adrenoreceptor Modulation on Patency of the Ductus Arteriosus.
LID - 10.3390/cells9122625 [doi]
LID - 2625
AB  - beta3-adrenoreceptor (beta3-AR), a G-protein coupled receptor, has peculiar regulatory 
      properties in response to oxygen and widespread localization. beta3-AR is expressed 
      in the most frequent neoplasms, also occurring in pregnant women, and its 
      blockade reduces tumor growth, indicating beta3-AR-blockers as a promising 
      alternative to antineoplastic drugs during pregnancy. However, beta3-AR involvement 
      in prenatal morphogenesis and the consequences of its blockade for the fetus 
      remain unknown. In this study, after the demonstrated expression of beta3-AR in 
      endothelial and smooth muscle cells of ductus arteriosus (DA), C57BL/6 pregnant 
      mice were acutely treated at 18.5 of gestational day (GD) with indomethacin or 
      with the selective beta3-AR antagonist SR59230A, or chronically exposed to SR59230A 
      from 15.5 to 18.5 GD. Six hours after the last treatment, fetuses were collected. 
      Furthermore, newborn mice were treated straight after birth with BRL37344, a 
      beta3-AR agonist, and sacrificed after 7 h. SR59230A, at the doses demonstrated 
      effective in reducing cancer progression (10 and 20 mg/kg) in acute and chronic 
      mode, did not induce fetal DA constriction and did not impair the DA ability to 
      close after birth, whereas at the highest dose (40 mg/kg), it was shown to cause 
      DA constriction and preterm-delivery. BRL37344 administered immediately after 
      birth did not alter the physiological DA closure.
FAU - Pini, Alessandro
AU  - Pini A
AUID- ORCID: 0000-0001-9828-2082
AD  - Department of Experimental and Clinical Medicine, University of Florence, 50139 
      Florence, Italy.
FAU - Fazi, Camilla
AU  - Fazi C
AD  - Department of Health Sciences, University of Florence, 50139 Florence, Italy.
FAU - Nardini, Patrizia
AU  - Nardini P
AUID- ORCID: 0000-0003-2374-5147
AD  - Department of Experimental and Clinical Medicine, University of Florence, 50139 
      Florence, Italy.
FAU - Calvani, Maura
AU  - Calvani M
AUID- ORCID: 0000-0003-0750-4706
AD  - Department of Paediatric Haematology-Oncology, A. Meyer University Children's 
      Hospital, 50139 Florence, Italy.
FAU - Fabbri, Sergio
AU  - Fabbri S
AD  - Department of Neuroscience, Psychology, Drug Research and Child Health, Section 
      of Pharmacology and Toxicology, University of Florence, 50139 Florence, Italy.
FAU - Guerrini, Alessandro
AU  - Guerrini A
AUID- ORCID: 0000-0002-8224-4919
AD  - Department of Veterinary Medical Sciences, University of Bologna, 40064 Ozzano 
      dell'Emilia, Italy.
FAU - Forni, Giulia
AU  - Forni G
AD  - Department of Neuroscience, Psychology, Drug Research and Child Health, Section 
      of Pediatric Neurosciences, "A. Meyer" University Children's Hospital, 50139 
      Florence, Italy.
FAU - La Marca, Giancarlo
AU  - La Marca G
AD  - Department of Neuroscience, Psychology, Drug Research and Child Health, Section 
      of Pediatric Neurosciences, "A. Meyer" University Children's Hospital, 50139 
      Florence, Italy.
FAU - Rosa, Arianna Carolina
AU  - Rosa AC
AUID- ORCID: 0000-0002-6139-9241
AD  - Department of Scienza e Tecnologia del Farmaco, University of Turin, 10125 Turin, 
      Italy.
FAU - Filippi, Luca
AU  - Filippi L
AD  - Division of Neonatology and NICU, Department of Clinical and Experimental 
      Medicine, University of Pisa, 56126 Pisa, Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201207
PL  - Switzerland
TA  - Cells
JT  - Cells
JID - 101600052
RN  - 0 (3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate)
RN  - 0 (Adrenergic beta-3 Receptor Antagonists)
RN  - 0 (Ethanolamines)
RN  - 0 (Propanolamines)
RN  - 0 (Receptors, Adrenergic, beta-3)
RN  - 0 (Receptors, G-Protein-Coupled)
RN  - 5DZZ1926YW (BRL 37344)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adrenergic beta-3 Receptor Antagonists/*pharmacology
MH  - Animals
MH  - Animals, Newborn
MH  - Disease Models, Animal
MH  - Disease Progression
MH  - Ductus Arteriosus/drug effects/*metabolism
MH  - Ductus Arteriosus, Patent/drug therapy/*metabolism
MH  - Ethanolamines/pharmacology
MH  - Female
MH  - Indomethacin/pharmacology
MH  - Male
MH  - Maternal Exposure
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Pregnancy
MH  - Pregnancy, Animal
MH  - Propanolamines/pharmacology
MH  - Receptors, Adrenergic, beta-3/*metabolism
MH  - Receptors, G-Protein-Coupled/metabolism
MH  - Time Factors
PMC - PMC7762377
OTO - NOTNLM
OT  - cancer
OT  - ductus arteriosus
OT  - pregnancy
OT  - beta3-adrenorceptor
COIS- The authors declare no conflict of interest.
EDAT- 2020/12/11 06:00
MHDA- 2021/07/09 06:00
PMCR- 2020/12/07
CRDT- 2020/12/10 01:03
PHST- 2020/10/30 00:00 [received]
PHST- 2020/12/02 00:00 [revised]
PHST- 2020/12/06 00:00 [accepted]
PHST- 2020/12/10 01:03 [entrez]
PHST- 2020/12/11 06:00 [pubmed]
PHST- 2021/07/09 06:00 [medline]
PHST- 2020/12/07 00:00 [pmc-release]
AID - cells9122625 [pii]
AID - cells-09-02625 [pii]
AID - 10.3390/cells9122625 [doi]
PST - epublish
SO  - Cells. 2020 Dec 7;9(12):2625. doi: 10.3390/cells9122625.